N-benzyl-N'-methyl-2-imidazolidinone

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: N-benzyl-N'-methyl-2-imidazolidinone
• 英文别名: 1-methyl-3-benzyl-2-imidazolidone；1-Benzyl-3-methylimidazolidin-2-one
• 化学式: C₁₁H₁₄N₂O
• 分子量: 190.245
• InChiKey: NZHLXTSFAMAJJF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  23.6
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  tert-butyldimethylsilyl 2,6-bis(trifluoromethansulfonyloxy)phenyl ether 、 N-benzyl-N'-methyl-2-imidazolidinone 在 cesium fluoride 作用下， 以 乙腈 为溶剂， 反应 3.0h， 以43%的产率得到1-methyl-4-benzyl-6-(trifluoromethanesulfonyloxy)-2,3,4,5-tetrahydro-(1H)-1,4-benzodiazepin-5-one
  参考文献：
  名称：

  3-(Triflyloxy)benzynes 实现环状脲的区域控制环加成以合成 1,4-苯二氮卓衍生物

  摘要：

  报道了通过各种 3-(三氟甲磺酰氧基) 苄与 N-(对甲苯磺酰基) 咪唑啉-2-酮反应合成 1,4-苯二氮卓衍生物的通用方法。该反应系统提供带有三氟甲磺酰氧基的 1,4-苯二氮卓作为四种可能的区域异构体中的单一区域异构体。

  DOI：

  10.1055/s-0036-1591924
• 作为产物：
  描述：

  1-甲基-2-咪唑啉酮 、 溴甲苯 在 sodium hydride 作用下， 以 四氢呋喃 为溶剂， 反应 11.0h， 以91%的产率得到N-benzyl-N'-methyl-2-imidazolidinone
  参考文献：
  名称：

  3-(Triflyloxy)benzynes 实现环状脲的区域控制环加成以合成 1,4-苯二氮卓衍生物

  摘要：

  报道了通过各种 3-(三氟甲磺酰氧基) 苄与 N-(对甲苯磺酰基) 咪唑啉-2-酮反应合成 1,4-苯二氮卓衍生物的通用方法。该反应系统提供带有三氟甲磺酰氧基的 1,4-苯二氮卓作为四种可能的区域异构体中的单一区域异构体。

  DOI：

  10.1055/s-0036-1591924

文献信息

• DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS
  申请人：Matsuyama Hironori

  公开号：US20100004438A1

  公开（公告）日：2010-01-07

  An object of the present invention is to provide a medicinal drug much improved in anti tumor activity and excellent in safety. According to the present invention, there is provided a medicinal drug containing a compound represented by the following general formula (1) or a salt thereof as an active ingredient: [Formula 1] wherein X 1 represents a nitrogen atom or a group —CH═, R 1 represents a group -Z-R 6 , in which Z represents a group —CO—, a group —CH(OH)— or the like, R 6 represents a 5- to 15-membered monocyclic, dicyclic or tricyclic saturated or unsaturated heterocyclic group having 1 to 4 nitrogen atoms, oxygen atoms or sulfur atoms, R 2 represents a hydrogen atom or a halogen atom, Y represents a group —O—, a group —CO—, a group —CH(OH)— or a lower alkylene group, and A represents [Formula 2] wherein R 3 represents a hydrogen atom, a lower alkoxy group or the like, p represents 1 or 2, R 4 represents an imidazolyl lower alkyl group or the like.

  本发明的一个目的是提供一种在抗肿瘤活性方面大大改进且安全性优异的药物。根据本发明，提供了一种包含以下一般式（1）所表示的化合物或其盐作为活性成分的药物：[式1]其中X1代表氮原子或基团—CH═，R1代表一个基团-Z-R6，其中Z代表基团—CO—，基团—CH(OH)—或类似的基团，R6代表一个含有1至4个氮原子、氧原子或硫原子的5至15个成员的单环、双环或三环饱和或不饱和杂环基团，R2代表氢原子或卤原子，Y代表基团—O—，基团—CO—，基团—CH(OH)—或低碳烷基基团，A代表[式2]其中R3代表氢原子、低碳氧基基团或类似基团，p代表1或2，R4代表咪唑基低碳基团或类似基团。
• Aromatic Compounds
  申请人：Fukushima Tae

  公开号：US20070270422A1

  公开（公告）日：2007-11-22

  The present invention provides a novel compound, which has an excellent effect of suppressing the generation of collagen and less side effects, with being excellent in terms of safety. The compound of the present invention is represented by the following general formula (1): [wherein X 1 represents a nitrogen atom or a group —CH═; R 1 represents a group -Z-R 6 , wherein Z represents a group —CO—, a group —CH(OH)—, or the like, and R 6 represents a 5- to 15-membered monocyclic, dicyclic, or tricyclic, saturated or unsaturated heterocyclic group having 1 to 4 nitrogen atoms, oxygen atoms, or sulfur atoms; R 2 represents a hydrogen atom, a halogen atom or a lower alkylene group; Y represents a group —O—, a group —CO—, a group —CH(OH)—, a lower alkylene group, or the like; and A represents a group or the like, wherein R 3 represents a hydrogen atom, a lower alkoxy group, or the like, p represents 1 or 2, and R 4 represents an imidazolyl lower alkyl group or the like.

  本发明提供了一种新型化合物，具有抑制胶原生成的优异效果，并且具有较少的副作用，在安全性方面表现出色。本发明的化合物由以下通式（1）表示：[其中X1代表氮原子或基团—CH═；R1代表基团-Z-R6，其中Z代表基团—CO—、基团—CH(OH)—或类似基团，而R6代表具有1到4个氮原子、氧原子或硫原子的5-到15元的单环、双环或三环、饱和或不饱和杂环基团；R2代表氢原子、卤素原子或低碳链基团；Y代表基团—O—、基团—CO—、基团—CH(OH)—、低碳链基团或类似基团；A代表基团或类似基团，其中R3代表氢原子、低碳醚基团或类似基团，p代表1或2，而R4代表咪唑基低碳基团或类似基团。
• AROMATIC COMPOUND
  申请人：FUKUSHIMA Tae

  公开号：US20120238750A1

  公开（公告）日：2012-09-20

  The compound of the present invention is represented by the following general formula (1): [wherein X 1 represents a nitrogen atom or a group —CH═; R 1 represents a group —Z—R 6 , wherein Z represents a group —CO—, a group —CH(OH)—, or the like, and R 6 represents a 5- to 15-membered monocyclic, dicyclic, or tricyclic, saturated or unsaturated heterocyclic group having 1 to 4 nitrogen atoms, oxygen atoms, or sulfur atoms; R 2 represents a hydrogen atom, a halogen atom or a lower alkylene group; Y represents a group —O—, a group —CO—, a group —CH(OH)—, a lower alkylene group, or the like; and A represents a group or the like, wherein R 3 represents a hydrogen atom, a lower alkoxy group, or the like, p represents 1 or 2, and R 4 represents an imidazolyl lower alkyl group or the like.

  本发明的化合物由以下通式（1）表示：[其中X1表示氮原子或基团—CH═; R1表示基团—Z—R6，其中Z表示基团—CO—、基团—CH（OH）—或类似物，而R6表示具有1至4个氮原子、氧原子或硫原子的5至15环的单环、双环或三环、饱和或不饱和的杂环基团; R2表示氢原子、卤素原子或较低的烷基链; Y表示基团—O—、基团—CO—、基团—CH（OH）—、较低的烷基链或类似物; A表示基团或类似物，其中R3表示氢原子、较低的烷氧基或类似物，p表示1或2，而R4表示咪唑基较低的烷基链或类似物。
• TRIAZOLE COMPOUNDS, AND PREPARATION METHOD THEREOF AND USE
  申请人：Wuhan LL Science And Technology Development Co., Ltd.

  公开号：EP3912974A1

  公开（公告）日：2021-11-24

  Disclosed are triazole compounds, and a preparation method thereof and use. The triazole compounds in the present invention have good LPAR1 antagonistic activity and selectivity, low toxicity, and good metabolic stability, and can be used for preventing or treating the LPAR1-related disease or disorder. The IC50 value of some compounds in the present invention can be below 300 nM, even 50 nM. All the compounds in the present invention have good safety, and the range of CC50 thereof can be greater than 200 µM. The compounds in the present invention have good metabolic stability in human, fancy rats, and house mice. The preparation method for the compounds in the present invention is simple, requires mild operation conditions, has high product yield, and is suitable for industrial production.

  本发明公开了三唑类化合物及其制备方法和用途。本发明中的三唑类化合物具有良好的 LPAR1 拮抗活性和选择性，毒性低，代谢稳定性好，可用于预防或治疗 LPAR1 相关疾病或紊乱。本发明中某些化合物的 IC50 值可以低于 300 nM，甚至 50 nM。本发明中的所有化合物都具有良好的安全性，其 CC50 的范围可以大于 200 µM。本发明中的化合物在人、花鼠和家鼠体内具有良好的代谢稳定性。本发明化合物的制备方法简单，操作条件温和，产品收率高，适合工业化生产。
• US7166603B2
  申请人：——

  公开号：US7166603B2

  公开（公告）日：2007-01-23